Entrada Therapeutics

Last week, the Entrada team attended Parent Project Muscular Dystrophy’s 2024 Annual Conference. Sweta Girgenrath, PhD, Vice President, Head of Cardiovascular and Neuromuscular Therapeutic Areas, presented preliminary data from our Phase 1 ENTR-601-44-101 trial for Duchenne muscular dystrophy. The team was also joined by Natarajan Sethuraman, PhD, Entrada’s Chief Scientific Officer.    We enjoyed speaking with patient advocacy organizations, families, key opinion leaders and industry professionals. We're ready to apply what we've learned. See you all next year!    #EntradaHere #Duchenne #DMD

Pride month has come to an end, but #PrideNeverEnds at Entrada. We stand as allies 365 days of the year, advocating for equal rights and creating a work environment where everyone can belong are a part of our core values.    Here are a few ways we live our commitment: · As a company we have publicly stated our commitment to diversity and apply DE&I principles across our work, every day  · Through our partnerships with patient advocacy organizations, we are actively working to identify and address discrimination and disparity in health care within both the Duchenne and rare disease communities · Our Pride committee sponsored a fireside chat and performance with prominent LGBTQ+ activist and drag performer, Candace Persuasian and Karla MacDonald, our Chief Corporate Affairs Officer · We are an active corporate member of OUTbio, supporting the 2nd OUTbio June Event  · We’ve partnered with Human Rights Campaign to support their annual gala and leverage their best practices in our benefits strategy · Our healthcare benefits include gender affirming care · We offer the opportunity to include our pronouns in our email signatures · Our Corporate and R&D site has a non-gendered restroom · We encourage and equip teammates to have courageous conversations · We use our Cultural Intelligence or CQ Chat on Microsoft Teams so that everyone can share and celebrate moments that are important to them   Join us on our journey: https://lnkd.in/eMt4CsU   #PrideMonth #PrideIs365 #EntradaHere

The deadline is quickly approaching for applications to the Entrada Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program! Entrada DREAMS is awarding three grants of $25,000 (USD) each to U.S. based non-profit organizations with project proposals that embrace diversity, inclusivity, accessibility and the creation or expansion of vital services to achieve greater equality within the Duchenne community. We are honored to be working with a talented independent review committee that includes neuromuscular specialists and patient advocates with expertise in Duchenne, Diversity, Equity, Inclusion & Access (DEIA), social impact and health: Sean Baumstark, Founder, de:terminence, Podcast Co-Host, Two Disabled Dudes Keisha Greaves, CEO & Founder, Girls Chronically Rock Amaris S., PsyD Aravindhan Veerapandiyan, MD The deadline to submit an application is July 12, 2024. To learn more and apply visit: www.entradatx.com/dreams #EntradaDREAMS #EntradaHere #DMD

It is that time of year again! We are excited about the caliber, experience and energy of the 2024 summer interns. Follow us on LinkedIn as we will be highlighting the work of our interns throughout the summer.   Please join us in welcoming our newest Entradans: ·      Marguerite Eno (Discovery Biology) ·      Colby Girard (Chemistry) ·      Yuva Gambhir (Finance) ·      Srinidhi Sriraman (Pharmacology) ·      Ruby O'Rourke (Human Resources) ·      Shreyaan Jain (Upstream Fermentation CMC) Are you interested in participating in our intern program? Bookmark our careers page now: https://lnkd.in/eMt4CsU   #EntradaHere #WelcomeInterns

Entrada Therapeutics announces $100 million registered direct offering. The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm. Learn more here: https://lnkd.in/dDZpdq4d

Entrada Therapeutics reports preliminary data in healthy volunteers from Phase 1 ENTR-601-44-101 trial for Duchenne muscular dystrophy. Learn more here: https://lnkd.in/dMPZtt9a

Yesterday, we celebrated Juneteenth by inviting Keisha Greaves to join us for a moderated discussion with our Entradans. Keisha is a rare disease and accessibility advocate with the city of Cambridge, CEO & Founder of Girls Chronically Rock and one of our judges for the DREAMS Grant Program. She was diagnosed with Limb-Girdle Muscular Dystrophy at the age of 24, and then went on to start Girls Chronically Rock, an adaptive clothing line meant to inspire and empower those with chronic illnesses. A big thank you to Keisha! We are incredibly grateful that you joined us. It was a valuable reminder of the many factors of true accessibility and the work needed to continue progressing forward. A special shoutout to the leader of Entrada's The Black ERG, Sara Blake, Research Associate II, Neuromuscular and Cardiac Biology, for facilitating the conversation. #EntradaHere #GirlsChronicallyRock #AccessibilityAwareness

We are looking forward to next week as Entrada will be attending Parent Project Muscular Dystrophy’s 2024 Annual Conference in Orlando, Florida. Sweta Girgenrath, PhD, Vice President, Head of Cardiovascular and Neuromuscular Therapeutic Areas, will be presenting during ‘Research Row: Strategies to Restore Dystrophin’ on Friday, June 28. The meeting celebrates three decades of progress, community and resilience. We hope to see you there June 27-29! Learn more here: https://lnkd.in/exuJZnwq #EntradaHere #Duchenne #DMD

Happy Juneteenth! Entrada’s offices are closed today in recognition of Juneteenth – or Freedom Day. Juneteenth is the longest historical celebration of Black history within the U.S. It is important for us to recognize and honor the significance of this day, especially as a community that strives for equality and justice. Join us as we make time to expand our knowledge, acknowledge the impact of structural racism and take steps toward positive change.   #Juneteenth #EntradaHere #Biotech

Today, we are celebrating our very own Leo Qian, PhD, Co-Founder & Vice President of Discovery Research at Entrada. He has been recognized by The Ohio State University with an ‘Emerging Leader Award’ as part of the 2024 Arts and Sciences Alumni Award honorees. This award recognizes a distinguished few alumni who have demonstrated distinctive and outstanding achievement in their profession and through civic involvement.   Congratulations, Leo! We are incredibly grateful for all your hard work and leadership.   To read Leo’s full bio, learn more about the award and other recipients, click here: https://lnkd.in/eu58QRA8   #EntradaHere #OhioState